Screener
CytomX Therapeutics CTMX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's free cash flow?
- CytomX Therapeutics (CTMX) reported free cash flow of -$18.07M in Q2 2026.
- How has CytomX Therapeutics's free cash flow changed year-over-year?
- CytomX Therapeutics's free cash flow decreased by 14.5% year-over-year, from -$15.78M to -$18.07M.
- What is the long-term trend for CytomX Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), CytomX Therapeutics's free cash flow has grown at a -11.0% compound annual growth rate (CAGR), from -$120.64M to -$75.81M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about CytomX Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude